Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT
Marianna Cortese,Kassandra L Munger,Elena H Martínez-Lapiscina,Christian Barro,Gilles Edan,Mark S Freedman,Hans-Peter Hartung,Xavier Montalbán,Frederick W Foley,Iris Katharina Penner,Bernhard Hemmer,Edward J Fox,Sven Schippling,Eva-Maria Wicklein,Ludwig Kappos,Jens Kuhle,Alberto Ascherio,BENEFIT Study Group,Siegrid Strasser-Fuchs,Thomas Berger,Karl Vass,Klaus V Toyka,Christian Sindic,Benedicte Dubois,Dominique Dive,Valerie Delvaux,Jan Debruyne,Luanne Metz,George Rice,Marcelo Kremenchutzky,Pierre Duquette,Yves Lapierre,Mark Freedman,A. John Petkau,Anthony Traboulse,Paul O'Connor,Petr Stourac,Radomir Talab,Martin Valis,Olga Zapletalova,Ivana Kovarova,Eva Medova,Jiri Fiedler,Jette Frederiksen,Bruno Broche,Thibault Moreau,Patrick Vermersc,Jean Pelletier,Michel Clanet,David Brassat,Pierre Clavelou,Christine Lebrun-Frenay,Olivier Gout,Mikko Kallela,Tuu Pirttila,Juhani Ruutiainen,Juha-Pek Erälinna,Keijo Koivisto,Mauri Reunanen,Irma Keskinarkaus,Irina Elovaara,Arno Villringer,Holger Altenkirch,Lars Bauer,Mario Ghazi,Christoph Pohl,Karl Wessel,Wolfgang Steinke,Bernd Kieseier,Hans Kölmel,Patrick Oschmann,Martin Berghoff,Ricarda Diem,Bernd Kitze,Alexander Dressel,Frank Hoffmann,Karl Baum,Stefan Jung,Hela-Felicit Petereit,Dirk Reske,Michael Sailer,Jürgen Köhler,Björn Tackenberg,Luisa Klotz,Reinhard Hohlfeld,Tania Kuempfel,Karl-Heinz Henn,Andreas Steinbrecher,Klemens Angstwurm,Hayrettin Tumani,Ralf Gold,Peter Rieckmann,Christoph Kleinschnitz,Samuel Komoly,Gyula Gacs,Gabor Jakab,Gyula Panczel,Tunde Csepany,Laszlo Csiba,Laszlo Vecsei,Ariel Miller,Dimitrios Karussis,Joab Chapman,Angelo Ghezzi,Giancarlo Comi,Vittorio Martinelli,Paolo Gallo,Vittorio Cosi,Roberto Bergamaschi,Luca Durelli,Paola Cavalla,Kjell-Morten Myhr,Andrzej Szczudlik,Krzysztof Selmaj,Zbigniew Stelmasiak,Halina Barosik-Psujek,Ryszard Podemski,Zdzislaw Maciejek,Slawomir Wawrzyniak,Luis Cunha,Sasa Sega-Jazbec,Txomin Arbizu,Albert Saiz Hinarejos,Joseba Barcena,Sergio Martínez Yélamos,Rafael Arroyo,Oscar Fernandez,Guillermo Izquierdo Ayuso,Bonaventura Casanova i Estruch,Jan Lycke,Ana de Vera,Stacey Wu,Ernst W. Radue,Heinrich Mattle,Karsten Beer,Jürg Kesselring,Frederik Barkhof,Chris H. Polman,Bernard Uitdehaag,Bert Anten,Raymond Hupperts,Leo Visser,Richard Coleman,Jeremy Chataway,David H. Miller,Jonathan O'Riordan,Stephen Howell,Henry F. McFarland
DOI: https://doi.org/10.1212/WNL.0000000000009371
IF: 9.9
2020-05-05
Neurology
Abstract:Objective: To investigate whether vitamin D, smoking, and anti-Epstein-Barr virus (EBV) antibody concentrations predict long-term cognitive status and neuroaxonal injury in multiple sclerosis (MS). Methods: This study was conducted among 278 patients with clinically isolated syndrome who participated in the clinical trial BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and completed the 11-year assessment (BENEFIT-11). We measured serum 25-hydroxyvitamin-D (25(OH)D), cotinine (smoking biomarker), and anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG) at baseline and at months 6, 12, and 24 and examined whether these biomarkers contributed to predict Paced Auditory Serial Addition Test (PASAT)-3 scores and serum neurofilament light chain (NfL) concentrations at 11 years. Linear and logistic regression models were adjusted for sex, baseline age, treatment allocation, steroid treatment, multifocal symptoms, T2 lesions, and body mass index. Results: Higher vitamin D predicted better, whereas smoking predicted worse cognitive performance. A 50-nmol/L higher mean 25(OH)D in the first 2 years was related to 65% lower odds of poorer PASAT performance at year 11 (95% confidence intervals [95% CIs]: 0.14-0.89). Standardized PASAT scores were lower in smokers and heavy smokers than nonsmokers (p trend = 0.026). Baseline anti-EBNA-1 IgG levels did not predict cognitive performance (p trend = 0.88). Associations with NfL concentrations at year 11 corroborated these findings-a 50-nmol/L higher mean 25(OH)D in the first 2 years was associated with 20% lower NfL (95% CI: -36% to 0%), whereas smokers had 20% higher NfL levels than nonsmokers (95% CI: 2%-40%). Anti-EBNA-1 antibodies were not associated with NfL. Conclusions: Lower vitamin D and smoking after clinical onset predicted worse long-term cognitive function and neuronal integrity in patients with MS.